替尔泊肽与司美格鲁肽的纵向系统建模定量分析
基于2型糖尿病28周临床试验数据构建机制性纵向模型,比较替尔泊肽15 mg与司美格鲁肽1 mg对空腹血糖的代谢效应。模型整合空腹血糖、胰岛素、胰岛素敏感性和β细胞功能,量化肝葡萄糖生成(HGP)并分离胰岛素非依赖性药物效应。结果显示替尔泊肽更优的空腹血糖控制主要由更强的胰岛素非依赖性HGP抑制驱动,低反应者存在HGP抑制缺陷。
要点
- 替尔泊肽15 mg优于司美格鲁肽1 mg的空腹血糖控制主要源于更强的胰岛素非依赖性HGP抑制。
- β细胞功能(HOMA-B)先升高后随胰岛素敏感性改善而下降,逆转经典T2D进展路径。
- 低反应者表现为HGP抑制不足,模拟增强HGP抑制可改善空腹血糖而不引起β细胞应激。
核心结论
- 替尔泊肽15 mg较司美格鲁肽1 mg改善空腹血糖更优,与更强的肝葡萄糖生成抑制相关。
- 靶向抑制肝葡萄糖生成的治疗策略可能带来超越直接增强β细胞功能或额外减重的代谢获益。
研究设计与样本
- 基于2型糖尿病患者接受替尔泊肽或司美格鲁肽治疗的28周临床试验数据,构建机制性纵向模型。
- 模型整合空腹血糖、空腹胰岛素、胰岛素敏感性和β细胞功能随时间的变化,量化HGP并分离胰岛素非依赖性药物效应。
主要发现
- β细胞功能(HOMA-B评估)先升高后随胰岛素敏感性改善而下降,逆转经典T2D进展路径。
- 替尔泊肽15 mg较司美格鲁肽1 mg的空腹血糖优势主要由更强的胰岛素非依赖性HGP抑制驱动。
- 低反应者存在HGP抑制缺陷,模拟增强HGP抑制可改善空腹血糖而不诱导与持续过度分泌相关的β细胞应激。
- 模拟增强减重可加速早期血糖改善,但未进一步降低长期空腹血糖水平。
临床怎么用
- 对于替尔泊肽或司美格鲁肽治疗低反应者,可考虑以增强HGP抑制为靶点的策略而非仅增加减重或β细胞功能增强。
- 临床评估疗效差异时需关注药物对肝葡萄糖生成的胰岛素非依赖性效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In a 28-week clinical trial of patients with type 2 diabetes (T2D), tirzepatide 15 mg (a dual GIP/GLP-1 receptor agonist) and semaglutide 1 mg (a GLP-1 receptor agonist) both improved fasting glucose, with tirzepatide showing superior efficacy. The longitudinal metabolic mechanisms underlying this difference remain incompletely defined. OBJECTIVE: To compare the longitudinal metabolic effects of tirzepatide and semaglutide using model-based analysis of fasting measures, elucidate underlying mechanisms, and explore strategies to enhance outcomes in low responders. METHODS: A mechanistic longitudinal model was developed based on the trial data from patients treated with tirzepatide or semaglutide. The model integrates fasting glucose, fasting insulin, insulin sensitivity, and beta-cell function over time, enabling quantification of hepatic glucose production (HGP) and isolation of insulin-independent drug effects on HGP. RESULTS: Beta-cell function, as assessed by HOMA-B, initially increased and then declined as insulin sensitivity improved, a reversal of the canonical T2D progression pathway. Tirzepatide's superior fasting glucose control versus semaglutide was driven primarily by greater insulin-independent suppression of HGP. Low responders exhibited deficient HGP suppression, and simulations suggested that enhancing HGP suppression improves fasting glucose without inducing β-cell stress associated with sustained hypersecretion. Simulated enhancement of weight loss accelerated early glycemic improvement but did not further reduce long-term fasting glucose levels. CONCLUSION: Greater suppression of hepatic glucose production was associated with greater efficacy of tirzepatide 15 mg versus semaglutide 1 mg in improving fasting glucose. Therapeutic strategies targeting suppression of hepatic glucose production may provide metabolic benefit beyond direct enhancement of beta-cell function or additional weight loss.
引用
- Yang B, Cabrera O, Mather KJ, et al. Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling. J Clin Endocrinol Metab. 2026. PMID: 42764204. doi:10.1210/clinem/dgag383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。